Anti-phospholipid antibody mediated fetal loss: Still an open question from a pathogenic point of view

Lupus

Volumn 19, Issue 4, 2010, Pages 453-456

  Meroni, P L ^a   Tedesco, F ^b   Locati, M ^a,c   Vecchi, A ^c   Di Simone, N ^d   Acaia, B ^e   Pierangeli, S S ^f   Borghi, M O ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c Shoulder and Elbow Unit   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Antiphospholipid antibodies; Complement; Fetal loss; Growth factor; Placenta

Indexed keywords

ACETYLSALICYLIC ACID; BETA2 GLYCOPROTEIN 1; CORTICOSTEROID; GROWTH FACTOR; HEPARIN; LIPOCORTIN 5; PHOSPHOLIPID ANTIBODY; PREDNISONE; SYNTHETIC PEPTIDE; TIFI PEPTIDE; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; CELL MEMBRANE; CLINICAL FEATURE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; DIABETES MELLITUS; DOSE RESPONSE; DRUG MECHANISM; FETOMATERNAL TRANSFUSION; FETUS; FETUS WASTAGE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOHISTOLOGY; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; INFLAMMATION; LOW DRUG DOSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT ABORTION; REPRODUCTION; REVIEW; SPONTANEOUS ABORTION; THROMBOGENESIS; THROMBOSIS;

ABORTION, HABITUAL; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CELL MEMBRANE; COMPLEMENT ACTIVATION; FEMALE; HUMANS; INFLAMMATION; NEUTROPHIL INFILTRATION; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOSIS;

EID: 77951211113     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309361351     Document Type: Review

References (16)

1. Pierangeli SS, Chen PP, Raschi E., et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008 ; 34: 236-250.
2. Rand JH, Wu XX, Guller S., et al. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994 ; 171: 1566-1572.
3. Park AL Placental pathology in antiphospholipid syndrome. In: Khamashta MA (ed.), Hughes syndrome, 2 nd edn. London: Springer ; 2006. p. 362-374.
4. Gerosa M., De Angelis V., Trespidi L., et al. Complement involvement in antiphospholipid antibody-mediated placental damage: prospective study in APS pregnant women. Ann Rheum Dis 2009 ; 68 (Suppl 3). 210.
5. Chaouat G. The Th1/Th2 paradigm: still important in pregnancy? Semin Immunopathol 2007 ; 29: 95-113. (Pubitemid 47603024)
6. Girardi G. Role of tissue factor in the maternal immunological attack of the embryo in the antiphospholipid syndrome Clin Rev Allergy Immunol 2009 Nov. 17; [Epub ahead of print].
7. Martinez de la Torre Y., Buracchi C., Borroni EM, et al. Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc Natl Acad Sci U S A 2007 ; 104: 2319-2324. (Pubitemid 46391395)
8. Redecha P., Salmon J. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004 ; 10: 1222-1226. (Pubitemid 39540439)
9. Cowchock FS, Reece EA, Balaban D., Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992 ; 166: 1318-1323.
10. Shamonki JM, Salmon JE, Hyjek E., Baergen RN Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007 ; 196: 167.e1-5.
11. Meroni PL, Gerosa M., Raschi E., Scurati S., Grossi C., Borghi MO Updating on the pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy loss. Clin Rev Allergy Immunol 2008 ; 34: 332-337.
12. Francis J., Rai R., Sebire NJ, et al. Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome. Mol Hum Reprod 2006 ; 12: 435-442. (Pubitemid 44288202)
13. Borghi MO, Raschi E., Broggini V., et al. Antiphospholipid antibody reactivity with human decidual cells: an additional mechanism of pregnancy complications in APS and a potential target for innovative therapeutic intervention. Ann Rheum Dis 2009 ; 68 (Suppl 3). 109.
14. Di Simone N., Marana R., Castellani R., et al. Decreased heparin-binding growth factor expression as a new pathogenic mechanism of the antiphospholipid-mediated defective placentation. Arthritis Rheum (in press).
15. Vega-Ostertag M., Liu X., Henderson V., Pierangeli SS A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid- mediated thrombosis in mice. Lupus 2006 ; 15: 358-365. (Pubitemid 44032711)
16. Martinez de la Torre Y., Raschi E., Borghi MO, et al. Pregnant nave mice are protected from aPL-induced foetal loss by the injection of a synthetic peptide (TIFI) mimicking the β2GPI PL-binding site. Arthritis Rheum 2008 ; 58 (Suppl): S404.